Dr. Lisa Staiano-Coico, senior associate dean of research, moderated the special breakfast seminar for the media on Jan. 30, co-sponsored by Weill Cornell and Pharmacia.
Weill Cornell and Pharmacia, a global-based pharmaceutical company located in Peapack, N.J., co-sponsored a special breakfast seminar for the media, on the topic "From Arthritis to Cancer: A New View of COX-2," on Jan. 30.
The event, held in the Uris Faculty Room (A-126), attracted writers and producers from WABC-TV, Glamour Magazine, Contemporary Surgery, Oncology Times, Drug Topics, and Drugstore News, among other media.
The seminar focused on the latest news on cyclooxygenase-2 (COX-2), an enzyme associated with inflammation and implicated in many cancers. COX-2 was discussed as a novel target for cancer treatment and prevention. Participants were also treated to a half-hour, hands-on laboratory experience on COX-2 expression, led by Dr. Kotha Subbaramaiah, assistant professor of medicine.
Dr. Lisa Staiano-Coico, senior associate dean of research, moderated the event. Dr. Andrew Dannenberg, the Henry R. Erle M.D.—Roberts Family Professor of Medicine and director of cancer prevention at Weill Cornell, presented "A Novel Pharmacological Target for Prevention and Treatment of Cancer." Dr. Mark Pochapin, chief of endoscopy and associate professor of clinical medicine at Weill Cornell, and Dr. Nasser Altorki, chief of endoscopy and professor of cardiothoracic surgery, presented "Meet the Experts: Current Phase II and III Research."